ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Genetic Biomarkers"

  • Abstract Number: 170 • 2013 ACR/ARHP Annual Meeting

    Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study

    Jasvinder A. Singh1,2, Ana Vazquez3, Richard Reynolds3, Vinodh Srinivasasainagendra4, S. Louis Bridges Jr.5 and David Allison3, 1Rheumatology, Birmingham VA, Birmingham, AL, 2Department of Medicine, University of Alabama, Tuscaloosa, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of alabama at birmingham, birmingham, AL, 5Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: We aim to assess the association of 8 serum urate SNPs and BMI and their interactions with incident gout in a population-based cohort study. Methods:…
  • Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting

    HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study

    Hiroshi Furukawa1, Shomi Oka1, Kota Shimada2, Shoji Sugii2, Atsushi Hashimoto3, Akiko Komiya1, Naoshi Fukui1, Taiichiro Miyashita4, Kiyoshi Migita4, Akiko Suda5, Shouhei Nagaoka6, Naoyuki Tsuchiya7 and Shigeto Tohma1, 1Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 3Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 4Clinical Research Center, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, 5Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 6Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, 7Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…
  • Abstract Number: 157 • 2013 ACR/ARHP Annual Meeting

    Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 168 Single Nucleotide Polymorphisms In The Optima Study

    Jeffrey F. Waring1, Viswanath Devanarayan2, Kenneth Idler1, Feng Hong2, Josef S. Smolen3, Arthur Kavanaugh4, Hartmut Kupper5, Hendrik Schulze-Koops6 and Alla Skapenko7, 1AbbVie Inc., North Chicago, IL, 2AbbVie Bioresearch Center, Worchester, MA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4University of California San Diego, La Jolla, CA, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6Division of Rheumatology, University of Munich, Munich, Germany, 7Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany

    Background/Purpose: Genetic factors have been identified that may be associated with the development and severity of rheumatoid arthritis (RA), disease progression, or response to treatment.…
  • Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting

    Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis

    Maureen D. Mayes for the US Scleroderma GWAS Group1, Lara Bossini-Castillo for the Spanish Scleroderma Group2, Olga Gorlova3, Jose Ezequiel Martin4, Xiaodong Zhou1, Wei Chen5, Shervin Assassi1, Jun Ying5, John D. Reveille1, Peter K. Gregersen6, Annette T. Lee7, Maria Teruel8, Francisco David Carmona4, Bobby P.C. Koeleman9, Matthew A. Brown and the Immunochip Consortium10, Christopher P. Denton11, Murray Baron for the Canadian Scleroderma Research Group12, Jasper Broen13, T.R.D.J. Radstake13 and Javier Martin4, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 5Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, 6Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 7Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 8Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 9Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 10Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 11Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 12Rheumatology, Jewish General Hospital, Montreal, QC, Canada, 13Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
  • Abstract Number: 2726 • 2013 ACR/ARHP Annual Meeting

    A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study

    Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia

    Background/Purpose: Chronic inflammation is believed to be responsible for accelerated atherosclerotic cardiovascular disease (CVD) in patients with SLE. Macrophage migration inhibitory factor (MIF) is a…
  • Abstract Number: 2558 • 2013 ACR/ARHP Annual Meeting

    Bone Morphogenic Protein Receptor 2 (BMPR2) Gene Mutations Are Associated To The Development Of Isolated Pulmonary Arterial Hypertension (PAH) In Systemic Sclerosis (SSc) Patients

    Tatiana Sofia Rodriguez-Reyna1, Jose Luis Hernandez-Oropeza2, Tomas Rene Pulido-Zamudio3, Felipe Massó4, Jessica Gutierrez-Manjarrez1, Alexandra Rueda de Leon-Aguirre1, Julio Sandoval-Zarate3 and Carlos Rodriguez-Osorio5, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 2Pulmonary Circulation Clinic, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 3Pulmonary Circulation Clinic, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 4Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5Intensive Care Unit, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Background/Purpose: Isolated pulmonary arterial hypertension (PAH) secondary to Systemic Sclerosis (SSc) is a severe life-threatening complication. Several pathogenic pathways have been implicated in its development.…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology